<SEC-DOCUMENT>0001178913-22-004307.txt : 20221212
<SEC-HEADER>0001178913-22-004307.hdr.sgml : 20221212
<ACCEPTANCE-DATETIME>20221212070022
ACCESSION NUMBER:		0001178913-22-004307
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20221212
FILED AS OF DATE:		20221212
DATE AS OF CHANGE:		20221212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		221456111

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2228876.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 22.10.1.5080
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
  <div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif;"><font style="font-weight: bold;">UNITED STATES&#160;</font>&#160;&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">Washington, D.C.&#160;20549</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">Report of Foreign Private Issuer</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">of&#160;the Securities Exchange Act of 1934</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif;">For the month of December 2022<br>
      Commission File No.:001-35773</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 18pt; font-weight: bold;">REDHILL BIOPHARMA LTD.</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif;">(Translation of registrant&#8217;s name into English)</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">21 Ha'arba'a Street, Tel Aviv, 6473921, Israel</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif;">(Address of principal executive offices)</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; font-family: 'Times New Roman', serif;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.&#160;</div>
    <div style="text-align: center; text-indent: 14.2pt; line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: center; text-indent: 14.2pt; line-height: 1.25; font-family: 'Times New Roman', serif;">Form 20-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160;&#160; Form 40-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-indent: 14.2pt; line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; font-family: 'Times New Roman', serif;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by Regulation S-T Rule
      101(b)(1): ____&#160;</div>
    <div style="text-indent: 28.35pt; line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; font-family: 'Times New Roman', serif;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by Regulation S-T Rule
      101(b)(7): ____</div>
    <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">Attached hereto and incorporated herein by reference is the notice of an extraordinary general meeting of the shareholders of RedHill Biopharma
      Ltd. scheduled for January 24, 2023.&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the
        Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019
        (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099) and on June 27, 2022 (File No. 333-265845), and its Registration Statements on Form F-3 filed with the
        Securities and Exchange Commission on March 30, 2021 (File No. 333-254848) and on July 29, 2021 (File No. 333-258259).</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%--></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">Signatures</div>
    <div style="text-indent: 28.35pt; line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;">Pursuant to the requirements of&#160;the&#160;Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
      the undersigned, thereunto duly authorized.&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z2a5f6831d2904410980073daf7d326b6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.95%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 33.61%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">REDHILL BIOPHARMA LTD.</div>
          </td>
          <td style="width: 16.43%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.95%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 33.61%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">(the "Registrant")</div>
          </td>
          <td style="width: 16.43%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.95%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 33.61%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 16.43%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.95%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">Date: December 12, 2022</div>
          </td>
          <td style="width: 33.61%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">By: /s/&#160;<font style="font-style: italic;">Dror Ben-Asher</font>&#160;&#160;</div>
          </td>
          <td style="width: 16.43%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.95%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 33.61%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">Dror Ben-Asher&#160;</div>
          </td>
          <td style="width: 16.43%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.95%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 33.61%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">Chief Executive Officer</div>
          </td>
          <td style="width: 16.43%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;<font style="font-weight: bold;">REDHILL BIOPHARMA LTD.</font><br>
      <font style="font-weight: bold;">21 Ha'arba'a Street</font></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">Tel-Aviv 6473921</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">Israel</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">To be held on January 24, 2022</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">The Extraordinary General Meeting of Shareholders of RedHill Biopharma Ltd. (the &#8220;Company"), will be held at the offices of
      the Company, 21 Ha'arba'a Street, Tel-Aviv, Israel on January 24, 2023, at 3:00 p.m. Israel time, or at any adjournments thereof (the "General Meeting"), for the following purposes:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z3c9e3f1d18164aa9bb1a0ca347c388de" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',serif;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', serif;">To approve a grant of restricted share units ("RSUs"), each with respect to one American Depository Share ("ADS") (each representing 10 ordinary shares, par value NIS 0.01 per
              share) ("Ordinary Shares") of the Company to the non-executive directors of the Company; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z0554b00d2208468a9561a73fabeab2ad" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',serif;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', serif;">To approve the increase of the Company's authorized share capital.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-family: 'Times New Roman', serif;">The Company is currently unaware of any other matters that may be raised at the General Meeting. Should any other matters
      be properly raised at the General Meeting, the persons designated as proxies shall vote according to their own judgment on those matters.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">Only holders of record of Ordinary Shares and holders of record of ADSs, evidenced by American Depositary Receipts issued by
      The Bank of New York Mellon at the close of business on December 19, 2022 shall be entitled to receive notice of and to vote at the General Meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-family: David, sans-serif;"><font style="color: #000000;">The Board of Directors recommends that you vote
        FOR the proposals, as specified on the proxy to be provided separately</font><font style="font-family: 'Times New Roman', serif;">.</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Whether or not you plan to attend the General Meeting, it is important that your ADSs or Ordinary Shares be
      represented. Accordingly, you are kindly requested to complete, date, sign and mail the proxy to be provided separately in the envelope provided at your earliest convenience so that it will be received no later than four hours prior to the General
      Meeting. Execution of a proxy will not in any way affect a shareholder&#8217;s right to attend the General Meeting and vote in person, and any person giving a proxy has the right to revoke it at any time before it is exercised.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;"><font style="color: #000000;">Shareholders who hold ordinary
          shares through members of the Tel-Aviv Stock Exchange Ltd. ("TASE"), who did not convert their ordinary shares to ADSs, may vote in the General Meeting in person or vote through the form of proxy card to be provided separately, which also serves
          as their voting card, by completing, dating, signing and mailing the proxy card to the Company&#8217;s offices so that it is received by the Company no later than Tuesday</font>, January 24, 2023<font style="color: #000000;"> at 11:00 a.m. Israel time, and must also provide the Company with a copy of their identity card, passport or certificate of incorporation (as the case may be), and an ownership certificate confirming their
          ownership of the Company&#8217;s ordinary shares on the Record Date. Such certificate must be approved by a recognized financial institution, as required by the Israeli Companies Regulations (Proof of Ownership of Shares for Voting at General Meeting)
          of 2000, as amended.</font></div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #0000FF; font-family: 'Times New Roman', serif;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 33.35pt; margin-left: 2.1pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">ADS holders should return their proxies by the date set forth on their form of
        proxy card.</div>
      <div style="text-align: justify; text-indent: 33.35pt; margin-left: 2.1pt; line-height: 1.25; color: #0000FF; font-family: 'Times New Roman', serif;">&#160;</div>
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-family: 'Times New Roman', serif;"><font style="color: #000000;">Shareholders wishing to express
        their position on an agenda item for this General Meeting may do so by submitting a written statement (</font>"<font style="color: #000000;">Position Statement</font>"<font style="color: #000000;">) to the Company&#8217;s offices, c/o Mr. Micha Ben Chorin, at 21 Ha'arba'a Street, Tel-Aviv, 6473921 Israel, by no later than Sunday, January 15, 2023. Any Position Statement received, that is
        in accordance with the guidelines set by the Israel Companies Law, will be furnished to the U.S. Securities and Exchange Commission (the "Commission</font>"<font style="color: #000000;">) on
        Form 6-K, and will be made available to the public on the Commission&#8217;s website at&#160;<u>http://www.sec.gov</u>.</font></div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">If within half an hour from the time appointed for the General Meeting a quorum is not present, the
      General Meeting shall be adjourned to the next business day following the day of the scheduled General Meeting, at the same time and place, or at another day, time and place prescribed by the Board of Directors in a notification to the shareholders.</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">This Notice and the documents mentioned therein, as well as the proposed resolutions on the agenda, can
      be viewed at the Company's registered office on 21 Ha'arba'a Street, Tel-Aviv, Israel, Tel: +972 3 541 3131, Sunday through Thursday between 10:00-15:00, and also will be made available to the public on the Company's website
      http://www.redhillbio.com, the Commission&#8217;s website at&#160;<u>http://www.sec.gov</u>.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z521aede51328446bb179f039bb74b40f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">By Order of the Board of Directors,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">Dror Ben-Asher</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">Chairman of the Board of Directors</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;">Tel-Aviv, Israel</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">December 12, 2022</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',serif;">3<br>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
